Comparative Pharmacology
Head-to-head clinical analysis: ESTROGEL versus NATURAL ESTROGENIC SUBSTANCE ESTRONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ESTROGEL versus NATURAL ESTROGENIC SUBSTANCE ESTRONE.
ESTROGEL vs NATURAL ESTROGENIC SUBSTANCE-ESTRONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Estradiol is a steroid hormone that binds to estrogen receptors (ERα and ERβ), activating gene transcription and non-genomic signaling pathways, leading to proliferation and differentiation of target tissues including breast, endometrium, and bone.
Estrone binds to and activates estrogen receptors (ERα and ERβ), leading to modulation of gene transcription and subsequent estrogenic effects on target tissues.
1.25 g (equivalent to 0.75 mg estradiol) applied once daily to upper arm or inner thigh; dose may be increased to 2.5 g (1.5 mg) depending on response.
0.1 to 0.5 mg intramuscularly 2 to 3 times per week for estrogen replacement therapy
None Documented
None Documented
The terminal elimination half-life of estradiol after transdermal administration is approximately 10–15 hours, supporting once-daily or twice-weekly dosing regimens. The half-life of estrone (major metabolite) is longer (12–20 hours), contributing to sustained estrogenic effects.
Terminal half-life: 24-48 hours (prolonged due to enterohepatic recirculation and tissue distribution).
Estradiol and its metabolites are primarily excreted in urine (≈90%) after conjugation (glucuronide and sulfate) in the liver, with the remainder eliminated in feces (≈10%) via bile. Less than 5% is excreted as unchanged parent drug.
Renal: ~50% (as glucuronide and sulfate conjugates), Biliary/Fecal: ~50% (enterohepatic recirculation).
Category C
Category C
Estrogen
Estrogen